Clinical Trial Search

Primary: Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug Treatment — 49; 43; 27; 30 participants — p=0.2587

Primary: Changes in Walking Distance After Three-months Intervention — 289.68; 262.95 meters

Primary: Change in WIQ Distance Subscore — 22.7; -7.2 Scale units

Primary: Diagnostic Accuracy — 36; 42; 55; 41 percentage

Primary: Lower Extremity Skeletal Muscle Glucose Uptake — 62.9; 48.6; 49.5 umol/kg/min

Primary: Maximum Walking Time From the Gardner Graded Treadmill Protocol — 117.7; 197.5; 188; 339.9 Seconds

Primary: Incidence of Major Cardiovascular Events — 112; 47; 51; 17 participants — p=<0.001

Primary: Effect of Intensive Lipid Modification Medication Therapy on Progression of Atherosclerosis and Restenosis of Femoral Arteries Measured Using High Resolution Magnetic…

Primary: Absolute Claudication Distance (ACD) — 54.374; 0.792 Meters

Primary: Effect of an Exercise Intervention on Walking Ability (Functional Outcome) — 301.4; 185.1 meters

Primary: Endothelial Function — 6.13; 3.78 % dilation

Primary: Peripheral Artery Disease (PAD) - Specific Health Status — 70.7; 66.9 units on a scale of 0-100

Primary: Positive Predictive Value of Digital ABI in Diagnosing PAD — 8; 2 Participants

Primary: Modified Physical Performance Test — 31.8; 32.3 scores on a scale

Primary: Plaque Volume — 10.5; 10.5; 10.8 cm^3 — p=0.32

Primary: Percentage of Participants With Clinically Relevant Bleeding During Treatment — 8; 11; 6; 6 percentage of participants

Primary: Device Technical Success — 29 lesions

Primary: Percent Change From Baseline in Initial Claudication Distance (ICD) at Week 12 — 21.99; 51.17 percent change — p=0.0041

Primary: The Proportion of Subjects With >50% Thrombolysis — 43.8; 47.4; 81.0; 47.4 percentage of participants

Primary: Change in the Mean Daily Walking Distance Over 7 Consecutive Days — 754.2; -1160 steps

Primary: Procedural Success of Endovascular PAD Treatment(s) — 83.6; 75.8; 68.5 percent of procedures

Primary: Mean Acute Flow Rate Difference During TUS Treatment Sessions — 27.3 Percent change (%)

Primary: Change in Absolute Claudication Distance (ACD) in Meters From Baseline — -16.8; -6.7; 76.2; -0.9 metres

Primary: Number of Participants With First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb…

Primary: Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 3 Months — 109; 56 seconds

Primary: Change in Six-minute Walk Distance — 32.3 Meters

Primary: Rate of Clinically Driven Target Lesion Revascularization (TLR) — 4.0; 8.2 % probablity of clinically driven TLR

Primary: Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at Baseline — 2.60; 1.98 meter/meter

Primary: Major Adverse Events (MAEs) Within 30 Days — 2 Participants

Primary: Technical Success — 144 lesion